People with HER2-positive metastatic breast cancer lived longer with Roche's Perjeta
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that people with HER-2 positive metastatic breast cancer (mBC) lived significantly longer (overall survival) when treated with the combination of PerjetaTM (pertuzumab), Herceptin® (trastuzumab) and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study.
Bristol-Myers Squibb and Emory University announce partnership
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and Emory University announced the formation of a strategic partnership to conduct clinical trials involving Bristol-Myers Squibb's investigational compounds.
AstraZeneca completes acquisition of Ardea Biosciences
- Details
- Category: AstraZeneca
AstraZeneca today announced that on Tuesday 19 June 2012 it completed its acquisition of San Diego, California-based biotechnology company Ardea Biosciences, Inc. The merger was approved by Ardea's stockholders.
Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and the Joslin Diabetes Center, a teaching and research affiliate of Harvard Medical School, announced a new collaboration to promote the development of new medicines for the treatment of diabetes and related disorders. The collaboration was unveiled at the 2012 Bio International Convention in Boston, Mass.
Takeda's exclusive distribution of Pfizer products in Japan
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited ("Takeda") and Pfizer Japan Inc. ("Pfizer") announced that they have concluded an agreement that, as of December 31, 2012, Takeda will cease distribution of 13 out of the 15 Pfizer products
Roche employees in 52 countries walk to raise funds to support vulnerable children worldwide
- Details
- Category: Roche
Over 20,000 employees of Roche from 113 Roche sites marked the International Day of the African Child by walking and collecting donations for children in need as part of the 9th Roche Children's Walk.
FDA approves Perjeta (pertuzumab) for people with HER2-positive metastatic breast cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved PerjetaTM (pertuzumab). Perjeta is approved in combination with Herceptin® (trastuzumab) and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
More Pharma News ...
- JDRF and Novo Nordisk establish R&D collaboration in type 1 diabetes
- Lilly expands strategic partnership with Chinese manufacturer Novast
- Novartis drug Gilenya® shows long-term efficacy and safety
- Bristol-Myers Squibb Foundation announces $6 million in grants
- Abbott presents phase 3 study results for investigational use of HUMIRA® (Adalimumab)
- ORENCIA® (abatacept) demonstrates comparable efficacy to Humira® (adalimumab)
- Trastuzumab emtansine (T-DM1) reduced the risk of cancer worsening or death